KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Enterprise Value (2016 - 2026)

Biogen has reported Enterprise Value over the past 18 years, most recently at -$4.3 billion for Q1 2026.

  • For Q1 2026, Enterprise Value fell 64.83% year-over-year to -$4.3 billion; the TTM value through Mar 2026 reached -$4.3 billion, down 64.83%, while the annual FY2025 figure was -$3.8 billion, 60.66% down from the prior year.
  • Enterprise Value for Q1 2026 was -$4.3 billion at Biogen, down from -$3.8 billion in the prior quarter.
  • Over five years, Enterprise Value peaked at -$1.0 billion in Q4 2023 and troughed at -$6.1 billion in Q2 2023.
  • A 5-year average of -$3.4 billion and a median of -$3.8 billion in 2022 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: soared 78.73% in 2024 and later crashed 141.84% in 2025.
  • Year by year, Enterprise Value stood at -$4.9 billion in 2022, then surged by 78.58% to -$1.0 billion in 2023, then plummeted by 126.21% to -$2.4 billion in 2024, then crashed by 60.66% to -$3.8 billion in 2025, then decreased by 12.24% to -$4.3 billion in 2026.
  • Business Quant data shows Enterprise Value for BIIB at -$4.3 billion in Q1 2026, -$3.8 billion in Q4 2025, and -$4.0 billion in Q3 2025.